[Indications for the use of tactivin in the combined treatment of phlegmons of the maxillofacial area]. 1996

V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina

The effects of subcutaneous and endolymphatic tactivin (in doses of 1 ml of 0.01% solution daily for 7 days) on clinical and immunological parameters were studied in patients with acute inflammations in the maxillofacial area, running a normo-, hypo-, and hyperergic course. Tactivin accelerated the arrest of inflammatory process and improved the patients' status, particularly so in cases with the hypo- and hyperergic inflammations. The key role in the mechanism of the drug action is played by increase of the immunoregulatory index, which reflects the increasing resistance of the body.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007571 Jaw Diseases Diseases involving the JAW. Disease, Jaw,Diseases, Jaw,Jaw Disease
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002481 Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions. Phlegmon
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005145 Face The anterior portion of the head that includes the skin, muscles, and structures of the forehead, eyes, nose, mouth, cheeks, and jaw. Faces
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1996, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1985, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1998, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1988, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 2006, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1987, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1986, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1994, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1983, Stomatologiia,
V Iu Drobyshev, and A I Volozhin, and V S Agapov, and T I Sashkina
January 1996, Stomatologiia,
Copied contents to your clipboard!